Covalent Modifiers

FEBRUARY 1, 2024

Therefore, understanding mechanisms by which acquired mutations in BTK confer drug resistance and developing new therapies to overcome resistance are critically important. We therefore set out to understand the nonenzymatic functions of BTK and explored targeted protein degradation to overcome the oncogenic scaffold function of mutant BTK.

Targeted Protein Degradation 68

Targeted Protein Degradation Clinical Trials Trials Science 68

The Pharma Data

JULY 22, 2021

This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer. Arvinas and Pfizer are seeking to develop ARV-471 as the potential endocrine therapy of choice for patients and their physicians.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

Drug Target Review

OCTOBER 4, 2023

Dual payload ADCs As effective as therapies have been in treating solid and haematological cancers, tumour heterogeneity and resistance remain major clinical challenges. To overcome these obstacles, combination therapy, which delivers multiple small molecules, has emerged as a potential solution. 1 , 33–43 (2018). 102 , 1–6 (2016).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn.,

Targeted Protein Degradation 52

Targeted Protein Degradation Engineering Clinical Trials Disease 52

Drug Target Review

JULY 23, 2024

Focusing on my time as Head of Research at Kymera, I’ve been fortunate to break new ground in drug discovery and development by advancing the science of targeted protein degradation (TPD) and progressing an industry leading pipeline to solve critical health problems that traditional medicines cannot address.

Small Molecule 115

Small Molecule Targeted Protein Degradation Science Disease 115

LifeSciVC

OCTOBER 28, 2024

During this time, novel science-heavy platforms were “hot” and well-funded: CRISPR, gene therapy, CAR-T, Targeted Protein Degradation, oligo/mRNAs, next gen chemistry, ADCs, Radiopharm, bispecifics… Truly an amazing period, and Atlas started and backed a number of great stories during this period (e.g.,

Licensing 92

Licensing Licensing Marketing Targeted Protein Degradation 92

The Pharma Data

SEPTEMBER 15, 2020

Amgen is a proud sponsor of MBC BioLabs, assisting high-potential and innovative early-stage life science and biotech companies accelerating development of new therapies to improve human health. We look forward to interacting with Amgen ‘s scientific and therapeutic experts to help move Trilomer® therapies into the clinic.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

Elrig

MARCH 22, 2023

Right now, targeted protein degradation is a critical focus topic across both industry and academia. All the techniques being discussed have profound consequences for future therapies, so the talks will be immensely valuable,” said Dr Herzog.

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40